Skip to content

Paratek says may file marketing application for antibiotic in early ’18

April 3, 2017

Paratek Pharmaceuticals Inc. PRTK, -3.38% shares surged in the extended session Monday after the small biotech company reported a late-stage study of its bacterial pneumonia drug met its endpoints. Paratek shares jumped 30% to $24.10 after hours, following a brief trading halt. The company said its community-acquired bacterial pneumonia antibiotic omadacycline was not inferior to the antibiotic moxifloxacin. Paratek said it plans to file a marketing application with the Food and Drug Administration as early as the first quarter of 2018.

http://on.mktw.net/2ouQQjc

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: